Eli Lilly Will Buy Loxo Oncology for $8 Billion
Ashley Yeager | Jan 8, 2019
Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.
John Mendelsohn, Former MD Anderson Cancer Center President, Dies
John Mendelsohn, Former MD Anderson Cancer Center President, Dies
The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.
The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
AbbVie Wins Bidding War for Cancer Drugmaker
Bob Grant | Mar 5, 2015
The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.
Lavish Spending at MD Anderson
Kate Yandell | May 28, 2013
The public cancer center is criticized for allegedly devoting at least $1.5 million to remodeling an executive suite.
Spinning Clinical Trials
Dan Cossins | Jan 16, 2013
Results of breast cancer drug trials are regularly spun to conceal bias and make the drugs seem more effective or less toxic than they really are.
$18M Grant to Be Re-reviewed
Jef Akst | Jun 1, 2012
A Texas cancer institute is taking a second look at the largest grant it ever awarded after concerns were raised that the proposal never received proper scientific review.